IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Rating) – Investment analysts at Capital One Financial issued their Q1 2023 earnings per share estimates for IDEAYA Biosciences in a research note issued on Monday, April 24th. Capital One Financial analyst Z. Jallah expects that the company will earn ($0.08) per share for the quarter. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.30) per share. Capital One Financial also issued estimates for IDEAYA Biosciences’ Q2 2023 earnings at ($0.40) EPS, Q4 2023 earnings at ($0.46) EPS, FY2024 earnings at ($2.35) EPS, FY2025 earnings at ($3.05) EPS, FY2026 earnings at ($2.71) EPS and FY2027 earnings at $0.33 EPS.
IDEAYA Biosciences (NASDAQ:IDYA – Get Rating) last posted its quarterly earnings data on Tuesday, March 7th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.07. The business had revenue of $4.02 million during the quarter, compared to the consensus estimate of $7.80 million. IDEAYA Biosciences had a negative return on equity of 18.38% and a negative net margin of 115.17%.
IDEAYA Biosciences Price Performance
Shares of NASDAQ:IDYA opened at $18.56 on Thursday. IDEAYA Biosciences has a 1-year low of $8.14 and a 1-year high of $21.00. The business has a fifty day moving average price of $15.66 and a 200-day moving average price of $16.65. The company has a market capitalization of $898.12 million, a PE ratio of -13.35 and a beta of 0.84.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Ensign Peak Advisors Inc boosted its position in IDEAYA Biosciences by 5.7% in the third quarter. Ensign Peak Advisors Inc now owns 100,171 shares of the company’s stock worth $1,495,000 after purchasing an additional 5,390 shares during the last quarter. Logos Global Management LP lifted its position in shares of IDEAYA Biosciences by 10.3% during the 3rd quarter. Logos Global Management LP now owns 4,135,000 shares of the company’s stock valued at $61,694,000 after buying an additional 385,000 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of IDEAYA Biosciences during the 3rd quarter valued at about $149,000. International Biotechnology Trust PLC lifted its position in shares of IDEAYA Biosciences by 7,161.8% during the 3rd quarter. International Biotechnology Trust PLC now owns 109,000 shares of the company’s stock valued at $1,625,000 after buying an additional 107,499 shares in the last quarter. Finally, Tekla Capital Management LLC purchased a new position in shares of IDEAYA Biosciences during the 3rd quarter valued at about $1,987,000. 94.20% of the stock is owned by hedge funds and other institutional investors.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
Read More
- Get a free copy of the StockNews.com research report on IDEAYA Biosciences (IDYA)
- 10 E-commerce Stocks to Consider for Long-Term Buys
- Joby Aviation Extends Deal With Air Force, Analysts Maintain Hold
- Meta’s Earnings; Time To Buckle Up
- Why Invest in High-Yield Dividend Stocks?
- Dividend Prince Automatic Data Processing Hits Bottom
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
